Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$41.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Lishan Aklog
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 41
- Beta
- 0.54
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -12.86
Financials
Revenue
$41.0K-79.5%Net Income
$-13.04MEBITDA
$-6.71MFree Cash Flow
$2.45MEPS (diluted)
$-1.77Shares Outstanding (diluted)
6.64M+22336.2%Operating Expenses
$6.61MCash & Debt
$3.63MReturn of Capital
$0.00Revenue by Segment (annual)
$100.00MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $71.0K | $401.0K | $-5.63 |
| 2024 | $3.00M | $39.79M | $99.15 |
| 2023 | $2.45M | $-64.17M | $-274.92 |
| 2022 | $377.0K | $-88.98M | $-450.95 |
| 2021 | $500.0K | $-50.35M | $-293.92 |
| 2020 | $0.00 | $-34.28M | $-327.91 |
| 2019 | $0.00 | $-15.93M | $-249.27 |
| 2018 | $0.00 | $-17.97M | $-378.78 |
| 2017 | $0.00 | $-9.52M | $-346.50 |
| 2016 | $0.00 | $-5.65M | $-198.00 |
| 2015 | $0.00 | $-1.78M | $-60.07 |
| 2014 | $0.00 | $-548.8K | $-9.18 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.88
- Implied price
- $15.82
- Return from $1.14
- 69.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $7.86 — today's price is already 85.6% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | 41.7% | 48.2% | 53.7% | 58.5% | 62.8% |
| 3.0% | 48.9% | 55.7% | 61.5% | 66.6% | 71.1% |
| 8.0% | 56.2% | 63.3% | 69.4% | 74.7% | 79.4% |
| 13.0% | 63.4% | 70.9% | 77.2% | 82.8% | 87.7% |
| 18.0% | 70.6% | 78.4% | 85.1% | 90.8% | 96.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
150+200.00%Social Signal Score
Mentions (5)
- Newsseekingalpha.com·9d ago·Positive
PAVmed Inc. (PAVM) Q3 2026 Earnings Call Transcript PAVmed Inc. (PAVM) Q3 2026 Earnings Call Transcript
View source ↗ - Newsprnewswire.com·9d ago·Negative
…with FDA on PortIO and Octeris Conference call and webcast to be held today, November 13, at 8:30 AM EST NEW YORK, Nov. 13, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid"), Veris Health Inc. ("Veris"), and Octeris Medica…
View source ↗ - Newsprnewswire.com·23d ago·Neutral
…iness Update Conference Call and Webcast on November 13, 2026 Conference Call and Webcast at 8:30 AM ET NEW YORK, Oct. 30, 2026 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Friday, November 13, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D.
View source ↗ - Newsseekingalpha.com·100d ago·Positive
PAVmed Inc. (PAVM) Q2 2026 Earnings Call Transcript PAVmed Inc. (PAVM) Q2 2026 Earnings Call Transcript
View source ↗ - Newsprnewswire.com·100d ago·Negative
…r coverage policy for EsoGuard ® Conference call and webcast to be held today, August 14, at 8:30 AM EDT NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid"), Veris Health Inc. ("Veris"), and Octeris Medica…
View source ↗
Earnings
Mon, Mar 29(in 4 months)
Consensus estimate $-0.42 per share
Typical surprise -85.1% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Nov 13$-1.76 vs $-0.59miss
- Fri, Aug 14$-0.87 vs $-0.47miss
- Fri, May 15$-4.42 vs $-0.69miss
- Thu, Mar 26$-2.05 vs $-4.50beat
- Thu, Nov 13$-8.70 vs $-5.10miss
- Thu, Aug 14$-22.20 vs $-3.90miss
Estimates and results for PAVM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PAVM officers and directors.
- Bought
- $232k
- Sold
- $756k
6 trades
6 trades
- Glennon Michael Jbought
- Glennon Michael Jbought
- Glennon Michael Jbought
- Aklog Lishanbought
- Sirovich Matthewsold
- Sirovich Matthewsold
- Sirovich Matthewsold
- Sirovich Matthewsold
88 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PAVM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
